Literature DB >> 33912804

Fiducial marker migration following computed tomography-guided placement in the liver: a case report.

Karishma Khullar1, Survandita Tara Dhawan2, John Nosher3, Salma K Jabbour1.   

Abstract

Radiation therapy for liver tumors has been shown to provide a local control and overall survival benefit in patients with primary or oligometastatic liver tumors. However, accurate delineation of the target volume in intraabdominal tumors can be limited by diaphragmatic motion. In addition to image guidance during radiation therapy, computed tomography (CT)-guided fiducial marker placement can improve the accuracy of radiation treatment and optimize tumor control. Fiducial marker placement is often indicated in stereotactic body radiation therapy (SBRT) due to the ablative doses used as well as in proton therapy given that these markers are clearly visible on orthogonal kV image guidance and studies have suggested that their placement in liver tumors offers improved local control. However, fiducial marker migration is a rare risk associated with fiducial placement for which literature remains scarce. We report two separate cases of fiducial marker migrations from the liver into the inferior vena cava and right atrium which occurred following CT-guided placement without any resultant toxicity. Imaging using contrast-enhanced or volume navigation ultrasound techniques during fiducial marker deployment may mitigate the risk of fiducial marker migration and potential end-organ injury. Alternative techniques for motion management such as inspiratory or expiratory breath hold or use of residual lipiodol on imaging in patients who have undergone transarterial chemoembolization (TACE) should be considered as well to avoid potential complications from fiducial marker placement. 2021 AME Case Reports. All rights reserved.

Entities:  

Keywords:  Fiducial markers; hepatocellular carcinoma (HCC); liver oligometastases; stereotactic body radiation therapy (SBRT)

Year:  2021        PMID: 33912804      PMCID: PMC8060155          DOI: 10.21037/acr-20-153

Source DB:  PubMed          Journal:  AME Case Rep        ISSN: 2523-1995


  19 in total

1.  Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols.

Authors:  Masashi Mizumoto; Toshiyuki Okumura; Takayuki Hashimoto; Kuniaki Fukuda; Yoshiko Oshiro; Nobuyoshi Fukumitsu; Masato Abei; Atsushi Kawaguchi; Yasutaka Hayashi; Ayako Ookawa; Haruko Hashii; Ayae Kanemoto; Takashi Moritake; Eriko Tohno; Koji Tsuboi; Takeji Sakae; Hideyuki Sakurai
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

2.  SBRT Using Residual Lipiodol as Surrogate Fiducial for Image Guidance in the Treatment of Recurrent or Residual Hepatocellular Carcinoma.

Authors:  S Sioshansi; L Ding; T J Fitzgerald
Journal:  Pract Radiat Oncol       Date:  2013-03-25

Review 3.  Contrast-Enhanced Ultrasound of Focal Liver Masses: A Success Story.

Authors:  Stephanie R Wilson; Peter N Burns; Yuko Kono
Journal:  Ultrasound Med Biol       Date:  2020-02-12       Impact factor: 2.998

4.  Utility of real-time image fusion technology in ultrasonography-guided fiducial marker implantation for stereotactic body radiation therapy for liver tumors.

Authors:  Koji Tokunaga; Akihiro Furuta; Yusuke Iizuka; Hiroyoshi Isoda; Kaori Togashi
Journal:  Acta Radiol       Date:  2020-06-26       Impact factor: 1.990

5.  CT-guided implantation of intrahepatic fiducial markers for proton beam therapy of liver lesions: assessment of success rate and complications.

Authors:  Naveen M Kulkarni; Theodore S Hong; Avinash Kambadakone; Ronald S Arellano
Journal:  AJR Am J Roentgenol       Date:  2015-02       Impact factor: 3.959

6.  Marker seed migration in prostate localization.

Authors:  Matthew M Poggi; Dean A Gant; Wilfred Sewchand; William B Warlick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

7.  Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy.

Authors:  Hiroki Shirato; Toshiyuki Harada; Tooru Harabayashi; Kazutoshi Hida; Hideho Endo; Kei Kitamura; Rikiya Onimaru; Koichi Yamazaki; Nobuaki Kurauchi; Tadashi Shimizu; Nobuo Shinohara; Michiaki Matsushita; Hirotoshi Dosaka-Akita; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

8.  Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Theodore S Hong; Jennifer Y Wo; Beow Y Yeap; Edgar Ben-Josef; Erin I McDonnell; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Lipika Goyal; Janet E Murphy; Milind M Javle; John A Wolfgang; Lorraine C Drapek; Ronald S Arellano; Harvey J Mamon; John T Mullen; Sam S Yoon; Kenneth K Tanabe; Cristina R Ferrone; David P Ryan; Thomas F DeLaney; Christopher H Crane; Andrew X Zhu
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

9.  Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.

Authors:  Mary Feng; Krithika Suresh; Matthew J Schipper; Latifa Bazzi; Edgar Ben-Josef; Martha M Matuszak; Neehar D Parikh; Theodore H Welling; Daniel Normolle; Randall K Ten Haken; Theodore S Lawrence
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

10.  Cardiac embolization of an implanted fiducial marker for hepatic stereotactic body radiotherapy: a case report.

Authors:  Hooman Hennessey; David Valenti; Tatiana Cabrera; Valerie Panet-Raymond; David Roberge
Journal:  J Med Case Rep       Date:  2009-11-20
View more
  1 in total

1.  Migration of Calypso beacon transponders for hepatic stereotactic body radiotherapy: a report of two cases.

Authors:  Razan Amjad; Youstina Soliman; Michael Pereira; Alessandra Cassano-Bailey; Mark Vivian; Sankar Venkataraman; Maged Nashed
Journal:  AME Case Rep       Date:  2022-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.